US2024026002A1PendingUtilityA1

Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors

Assignee: XENCOR INCPriority: Nov 8, 2017Filed: Aug 18, 2023Published: Jan 25, 2024

Est. expiryNov 8, 2037(~11.3 yrs left)· nominal 20-yr term from priority

Inventors:Matthew J. Bernett Gregory Moore John Desjarlais Michael Hedvat Christine Bonzon

C07K 16/2818A61P 35/00A61P 37/06C07K 16/2803C07K 16/2827C07K 2317/55C07K 2317/622C07K 2317/64C07K 2317/76C07K 2317/52C07K 2317/33C07K 2317/31A61K 2039/507C07K 2317/92A61K 2039/505

PatentIndex Score

Cited by

References

Claims

Abstract

The present invention is directed to bispecific, heterodimeric immunomodulatory antibodies.

Claims

exact text as granted — not AI-modified

1 - 25 . (canceled) 
     
     
         26 . A method of treating cancer in a patient comprising administering:
 a) a therapeutically effective amount of a bispecific antibody comprising:
 i) a first monomer comprising the amino acid sequence of SEQ ID NO:29748; 
 ii) a second monomer comprising the amino acid sequence of SEQ ID NO:29749; and 
 iii) a third monomer comprising the amino acid sequence of SEQ ID NO:29750; and 
   b) a therapeutic effective amount of an anti-CTLA4 antibody.

Join the waitlist — get patent alerts

Track US2024026002A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.